OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $898,000 Stake in KalVista Pharmaceuticals, Inc. $KALV

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 53.2% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 79,460 shares of the specialty pharmaceutical company's stock after selling 90,232 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.16% of KalVista Pharmaceuticals worth $898,000 at the end of the most recent quarter.Several other hedge funds and other institutional investors have also recently bought and sold shares of KALV. Parkman Healthcare Partners LLC acquired a new stake in shares of KalVista Pharmaceuticals in the first quarter valued at about $8,698,000. Woodline Partners LP lifted its stake in shares of KalVista Pharmaceuticals by 25.5% in the first quarter. Woodline Partners LP now owns 1,617,469 shares of the specialty pharmaceutical company's stock worth $18,666,000 after acquiring an additional 329,068 shares during the period. Panagora Asset Management Inc. boosted its holdings in KalVista Pharmaceuticals by 307.0% in the second quarter. Panagora Asset Management Inc. now owns 292,593 shares of the specialty pharmaceutical company's stock valued at $3,308,000 after acquiring an additional 220,697 shares during the last quarter. Emerald Mutual Fund Advisers Trust boosted its holdings in KalVista Pharmaceuticals by 26.4% in the second quarter. Emerald Mutual Fund Advisers Trust now owns 768,972 shares of the specialty pharmaceutical company's stock valued at $8,693,000 after acquiring an additional 160,759 shares during the last quarter. Finally, Nan Fung Trinity HK Ltd. acquired a new stake in KalVista Pharmaceuticals during the 2nd quarter valued at approximately $1,747,000. Insider ActivityIn other KalVista Pharmaceuticals news, CFO Brian Piekos sold 4,471 shares of the firm's stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $13.45, for a total value of $60,134.95. Following the completion of the sale, the chief financial officer owned 10,529 shares of the company's stock, valued at approximately $141,615.05. This trade represents a 29.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Paul K. Audhya sold 5,296 shares of the business's stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $13.45, for a total value of $71,231.20. Following the sale, the insider owned 131,831 shares of the company's stock, valued at approximately $1,773,126.95. This represents a 3.86% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 31,329 shares of company stock worth $437,371 in the last three months. Company insiders own 4.30% of the company's stock. KalVista Pharmaceuticals Stock Up 0.2%KalVista Pharmaceuticals stock opened at $16.90 on Friday. The company has a quick ratio of 7.21, a current ratio of 7.22 and a debt-to-equity ratio of 8.18. KalVista Pharmaceuticals, Inc. has a 12-month low of $7.30 and a 12-month high of $17.28. The firm's fifty day moving average is $12.66 and its 200 day moving average is $13.14. The company has a market capitalization of $854.30 million, a PE ratio of -4.28 and a beta of -0.14. KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last posted its quarterly earnings results on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) EPS for the quarter, topping analysts' consensus estimates of ($0.96) by $0.04. The company had revenue of $13.69 million during the quarter, compared to analyst estimates of $6.03 million. As a group, sell-side analysts predict that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current fiscal year. Analyst Upgrades and DowngradesKALV has been the topic of a number of recent analyst reports. Citizens Jmp dropped their price target on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a "market outperform" rating on the stock in a research report on Tuesday, November 11th. Citigroup reissued a "market outperform" rating on shares of KalVista Pharmaceuticals in a research note on Tuesday, November 11th. JMP Securities boosted their target price on shares of KalVista Pharmaceuticals from $27.00 to $28.00 and gave the company a "market outperform" rating in a report on Friday, September 12th. Cowen reaffirmed a "buy" rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 3rd. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of KalVista Pharmaceuticals in a report on Wednesday, October 8th. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $26.63.Get Our Latest Stock Report on KALVKalVista Pharmaceuticals Company Profile (Free Report)KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).Further ReadingFive stocks we like better than KalVista PharmaceuticalsWhat is the Dow Jones Industrial Average (DJIA)?3 Recently Downgraded Stocks to Avoid in 20263 Tickers Leading a Meme Stock RevivalThe Chip Boom Is Back: 3 Stocks Positioned for Huge GainsConsumer Discretionary Stocks ExplainedOracle Stock Hit Hard: Why Its AI Pipeline Could Drive a 2026 RallyThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in KalVista Pharmaceuticals Right Now?Before you consider KalVista Pharmaceuticals, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KalVista Pharmaceuticals wasn't on the list.While KalVista Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here